Postmenopausal women. Unspecified menopausal and perimenopausal disorder
Conditions
Interventions
Intervention 1: Intervention group: This group was treated with vaginal probiotics containing live microorganisms.These probiotics, such as lactobacilli, when administered in adequate amounts, help im
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
45 Years to 60 Years
Inclusion criteria
Inclusion criteria: Women aged 45-60 who are experiencing one or more symptoms of menopause These individuals are unable to receive hormone replacement therapy due to contraindications, including abnormal vaginal bleeding, malignancy, deep vein thrombosis, pulmonary embolism, arterial thromboembolism, various thrombophilias, benign and malignant breast masses, liver disease, cardiovascular disease, suspected pregnancy, and allergies These individuals must provide informed consent to participate in the study
Exclusion criteria
Exclusion criteria: Women with premature menopause Women with a history of hysterectom Women with blindness Women with Deafness Women with severe illness (defined as death or patients receiving critical care) Women with a history of sensitivity to the drug sertraline Women consuming estrogenic drugs and estrogen-containing compounds such as fennel Women with mental illnesses such as schizophrenia Women who have been hospitalized in the past three months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in menopausal symptoms as measured by the total score of the Menopause Rating Scale (MRS). This scale is designed to assess the severity of menopausal symptoms across three main domains: Vasomotor symptoms (e.g., hot flashes, night sweats), Psychological symptoms (e.g., depression, anxiety, sleep disorders), Somatic symptoms (e.g., joint pain, vaginal dryness, and other physical issues).The MRS score was assessed at baseline (pre-intervention) and after 12 weeks of treatment (post-intervention) for each participant. The change in the total MRS score before and after the intervention was used as an indicator to evaluate the effectiveness of the interventions (vaginal probiotics vs. sertraline) in alleviating menopausal symptoms.Calculation Method: A reduction in the total MRS score after the intervention reflects an improvement in menopausal symptoms. The sample size of the study was determined based on this primary outcome variable. Timepoint: 12 weeks after the initiation of vaginal probiotics and sertraline. Method of measurement: Menopause Rating Scale questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMaryam Niksolat
Iran University of Medical Sciences
Outcome results
None listed